Am J Pathol

1. NELSON CA, Obray JD, Roll CR, Williams PE, et al
   Leukocytic Dopamine D2 Receptors as Biomarkers for Brain Dopamine Levels in Parkinson's Disease.
   Am J Pathol. 2026 Feb 1:S0002-9440(26)00028-3. doi: 10.1016/j.ajpath.2026.
   

   >> Share

   
   

   
   Biochemistry

2. DEVI M, Paul S
   Precision Interdiction of alpha-Synuclein Folding Pathways by Molecular Tweezers.
   Biochemistry. 2026;65:325-338.
   

   >> Share

   
   

   
   BMC Neurol

3. ZANG P, Liu Y, Hao Y
   Levodopa intolerance as a potential clinical red flag for neuronal intranuclear inclusion disease (NIID) in atypical parkinsonism: a case report.
   BMC Neurol. 2026 Feb 3. doi: 10.1186/s12883-026-04696.
   

   >> Share

   
   

   
   Brain Res

4. CAVALCANTI BEZERRA GOUVEIA HJ, Dos Santos-Junior OH, Frasnelli J, Fisette A, et al
   Ghrelin-based interventions in preclinical models of Parkinson's disease: a systematic review.
   Brain Res. 2026;1876:150187.
   

   >> Share

   
   

   
   Exp Neurol

5. WANG L, Wang Y, Yang S, Bai Y, et al
   Long-term continuous theta burst stimulation ameliorates L-DOPA-induced dyskinesia in Parkinsonian rats through modulation of the cerebello-thalamo-striatal circuit.
   Exp Neurol. 2026;399:115674.
   

   >> Share

   
   

   
   J Neural Transm (Vienna)

6. METTA V, Mridula R, Hosurkar G, Wadia P, et al
   Deep brain stimulation for Parkinson's disease in India: an expert consensus on availability, affordability, and eligibility by the Parkinson's research alliance India (PRAI).
   J Neural Transm (Vienna). 2026 Feb 3. doi: 10.1007/s00702-026-03106.
   

   >> Share

   
   

   
   J Neurochem

7. LEE HS, Kang SA, Eom JW, Kim MS, et al
   Zinc-Mediated Lysosomal Destabilization Links Mitochondrial Damage to Neuronal Death in a Cellular MPP(+) Model of Parkinson's Disease.
   J Neurochem. 2026;170:e70363.
   

   >> Share

   
   

   
   J Neurosci

8. ARMAKOLA M, Wilen AP, Bustos BI, Song P, et al
   In vivo screen of Parkinson's disease GWAS risk genes identifies ARIH2 as a novel regulator of alpha-synuclein toxicity in dopaminergic neurons.
   J Neurosci. 2026 Feb 6:e0509252026. doi: 10.1523/JNEUROSCI.0509-25.2026.
   

   >> Share

   
   

   
   Mov Disord

9. RAJAI FIROUZABADI S, Mohammadi I, Golsorkh H, Mahdavi S, et al
   Hearing Loss in Parkinson's Disease: A Systematic Review and Meta-Analysis.
   Mov Disord. 2026 Jan 30. doi: 10.1002/mds.70206.
   

   >> Share

   
   
10. NIEMI KJ, Kaasinen V, Weil RS, Joutsa J, et al
    Monoaminergic Networks of Cognitive and Behavioral Symptoms in Early Parkinson's Disease.
    Mov Disord. 2026 Jan 30. doi: 10.1002/mds.70199.
    

    >> Share

    
    
11. KOFOED RH, Hvingelby VS, Pineda-Pardo JA, Blesa J, et al
    Focused Ultrasound for the Treatment of Circuit and Molecular Pathology in Parkinson's Disease.
    Mov Disord. 2026 Feb 3. doi: 10.1002/mds.70156.
    

    >> Share

    
    
12. DARDOV VJ, Vasanthakumar A, Kulkarni A, Sundararaman N, et al
    Accelerating Medicines Partnership(R) Parkinson's Disease Proteomics: A Comprehensive Resource for Advancing Parkinson's Disease Research.
    Mov Disord. 2026 Feb 5. doi: 10.1002/mds.70183.
    

    >> Share

    
    

    
    Nature

13. BAEKELANDT V
    Immune cells from the gut drive development of Parkinson's disease in the brain.
    Nature. 2026 Feb 4. doi: 10.1038/d41586-026-00284.
    

    >> Share

    
    
14. REN J, Zhang W, Dahmani L, Gordon EM, et al
    Parkinson's disease as a somato-cognitive action network disorder.
    Nature. 2026 Feb 4. doi: 10.1038/s41586-025-10059.
    

    >> Share

    
    

    
    Neurobiol Dis

15. ZHENG Q, Lin X, Fei G, Xiao L, et al
    A neuropeptide receptor-enriched transcriptional state characterizes resilient dopaminergic neurons in Parkinson's disease.
    Neurobiol Dis. 2026;220:107303.
    

    >> Share

    
    
16. ATHIENITI E, Afxenti S, Minadakis G, Spyrou GM, et al
    Multi-omics dissection of Parkinson's patients in subgroups associated with motor and cognitive severity.
    Neurobiol Dis. 2026 Feb 2:107288. doi: 10.1016/j.nbd.2026.107288.
    

    >> Share

    
    
17. CUI J, Zhao D, Liu J, Qian J, et al
    Inhibition of the LHb glutamatergic pathway ameliorates depressive-like behaviors in a 6-hydroxydopamine-induced Parkinson's disease mouse model.
    Neurobiol Dis. 2026;220:107293.
    

    >> Share

    
    
18. ROTH LM, Morozova O, Stohr J, Schapansky J, et al
    Astrocytic lysosome deficits reduce alpha-synuclein degradation and induce the spread of pathology.
    Neurobiol Dis. 2026;219:107277.
    

    >> Share

    
    

    
    Neuroscience

19. CALZETTI S, Negrotti A
    Dopamine antagonists-induced parkinsonism: the crucial role of individual susceptibility associated to positive family history.
    Neuroscience. 2026 Jan 31:S0306-4522(26)00079.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

20. 
    Correction Paschou et al., Dysregulated proteostasis in p.A53T-alpha-Synuclein astrocytes aggravates Lewy-like neuropathology in a Parkinson's disease iPSC model.
    Proc Natl Acad Sci U S A. 2026;123:e2601834123.
    

    >> Share

    
    
21. OLCHANYI MD, Schreier DR, Li J, Maffei C, et al
    Probabilistic mapping and automated segmentation of human brainstem white matter bundles.
    Proc Natl Acad Sci U S A. 2026;123:e2509321123.
    

    >> Share

    
    
22. WRIGHT S, Dang VC, Hussain S, Kandel P, et al
    Selective peroxynitrite-mediated protein nitration catalyzed by glyoxalase domain containing protein 4.
    Proc Natl Acad Sci U S A. 2026;123:e2515002123.
    

    >> Share

    
    

    
    Rev Neurol (Paris)

23. TRAN HT, Huynh MBT
    Reliability and validity of the Vietnamese version of the Montreal Cognitive Assessment in Parkinson's disease.
    Rev Neurol (Paris). 2026 Feb 3:S0035-3787(26)00022.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share